Projects per year
Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 18 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Cancer Center Support Grant
Yee, D., AbuSalah, A. M., Basu, S., Beckman, K. B., Bielinsky, A. K., Cooley, S. A., De For, T. E., Falconer, S. N., Felices, M., Griffin, T. J., Hallstrom, T. C., Hatsukami, D. K., Hendrickson, E. A., Hirsch, B. A., Joseph, A. M., Kirstein, M. N., Konety, B. R., Koopmeiners, J., Kuntz, K. M., Lange, C. A., Largaespada, D. A., Le, C. T., LeBeau, A., Lindgren, B. R., Luo, X., Mc Carthy, J. B., McKenna, D. H., Miller, J. S., Moriarity, B. S., Nelson, H. H., O'Sullivan, G., Ondrey, F. G., Pennell, C. A., Petersen, A. J., Peterson, B. A., Peterson, L. A., Sarver, A. L., Shimizu, Y., Siegfried, J. M., Temiz, N. A., Turesky, R., Vogel, R., Wagner, J. E., Wang, J., Weigel, B. J., Weisdorf, D. J., Woo, J. & Yamamoto, M.
NIH NATIONAL CANCER INSTITUTE (NCI)
2/1/19 → 1/31/24
Project: Research project
Scientific Programmatic Leadership: NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant(UM1CA228823)
Children's Hospital of Philadelphia
9/20/18 → 7/31/23
Project: Research project
Mechanisms of Resistance to Immunotherapy in Osteosarcoma
Modiano, J., Farrar, M. A., Subramanian, S., Vallera, D. A. & Weigel, B. J.
9/1/18 → 8/31/20
Project: Research project
Research Output
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)
Schafer, E. S., Rau, R. E., Berg, S. L., Liu, X., Minard, C. G., Bishop, A. J. R., Romero, J. C., Hicks, M. J., Nelson, M. D., Voss, S., Reid, J. M., Fox, E., Weigel, B. J. & Blaney, S. M., Feb 1 2020, In : Pediatric Blood and Cancer. 67, 2, e28073.Research output: Contribution to journal › Article
A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: Children's Oncology Group Phase I and pilot Consortium (ADVL0921)
Mosse, Y. P., Fox, E., Teachey, D. T., Reid, J. M., Safgren, S. L., Carol, H., Lock, R. B., Houghton, P. J., Smith, M. A., Hall, D., Barkauskas, D. A., Krailo, M., Voss, S. D., Berg, S. L., Blaney, S. M. & Weigel, B. J., Jun 1 2019, In : Clinical Cancer Research. 25, 11, p. 3229-3238 10 p.Research output: Contribution to journal › Article
Open Access
5
Scopus
citations
Identification of aggressive Gardner syndrome phenotype associated with a de novo APC variant, c.4666dup
Kiessling, P., Dowling, E., Huang, Y., Ho, M. L., Balakrishnan, K., Weigel, B. J., Edward Highsmith, W., Niu, Z. & Schimmenti, L. A., Jan 1 2019, In : Cold Spring Harbor Molecular Case Studies. 5, 2, a003640.Research output: Contribution to journal › Article
Open Access
Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
Kopp, L. M., Malempati, S., Krailo, M., Gao, Y., Buxton, A., Weigel, B. J., Hawthorne, T., Crowley, E., Moscow, J. A., Reid, J. M., Villalobos, V., Randall, R. L., Gorlick, R. & Janeway, K. A., Nov 2019, In : European Journal of Cancer. 121, p. 177-183 7 p.Research output: Contribution to journal › Article
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group
Malempati, S., Weigel, B. J., Chi, Y. Y., Tian, J., Anderson, J. R., Parham, D. M., Teot, L. A., Rodeberg, D. A., Yock, T. I., Shulkin, B. L., Spunt, S. L., Meyer, W. H. & Hawkins, D. S., Jan 15 2019, In : Cancer. 125, 2, p. 290-297 8 p.Research output: Contribution to journal › Article
Open Access
6
Scopus
citations